Search research articles
Contact Us
Filters
Showing results (21-30 of 65) with videos related to
Page
of 7
Sort By:
JAMA Neurology
|
May 12, 2020
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders
Antoine Leuzy, Ruben Smith, Rik Ossenkoppele, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
June 9, 2022
In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model
Roxana Aldea, Hans Peter Grimm, Ronald Gieschke, et al.
Journal of Comparative Effectiveness Research
|
October 30, 2012
Prioritizing comparative effectiveness research for cancer diagnostics using a regional stakeholder approach
Gregory Klein, Laura S Gold, Sean D Sullivan, et al.
Alzheimer'S Research & Therapy
|
December 14, 2019
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis
Gregory Klein, Paul Delmar, Nicola Voyle, et al.
Plos Biology
|
July 21, 2025
Personalised regional modelling predicts tau progression in the human brain
Pavanjit Chaggar, Jacob W Vogel, Alexa Pichet Binette, et al.
Alzheimer'S Research & Therapy
|
November 29, 2022
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease
Randall J Bateman, Jeffrey Cummings, Scott Schobel, et al.
Biorxiv : the Preprint Server for Biology
|
February 9, 2026
Dynamical A <i>β</i> -Tau-Neurodegeneration Model Predicts Alzheimer's Disease Mechanisms and Biomarker Progression
Pavanjit Chaggar, Jacob W Vogel, Travis B Thompson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 14, 2022
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients
Ruben Smith, Nicholas C Cullen, Alexa Pichet Binette, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
January 31, 2025
Biomarker treatment effects in two phase 3 trials of gantenerumab
Tobias Bittner, Matteo Tonietto, Gregory Klein, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 3, 2014
The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data
Mark E Schmidt, Ping Chiao, Gregory Klein, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 65) with videos related to
Sort By:
Page
of 7
JAMA Neurology
|
May 12, 2020
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders
Antoine Leuzy, Ruben Smith, Rik Ossenkoppele, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
June 9, 2022
In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model
Roxana Aldea, Hans Peter Grimm, Ronald Gieschke, et al.
Journal of Comparative Effectiveness Research
|
October 30, 2012
Prioritizing comparative effectiveness research for cancer diagnostics using a regional stakeholder approach
Gregory Klein, Laura S Gold, Sean D Sullivan, et al.
Alzheimer'S Research & Therapy
|
December 14, 2019
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis
Gregory Klein, Paul Delmar, Nicola Voyle, et al.
Plos Biology
|
July 21, 2025
Personalised regional modelling predicts tau progression in the human brain
Pavanjit Chaggar, Jacob W Vogel, Alexa Pichet Binette, et al.
Alzheimer'S Research & Therapy
|
November 29, 2022
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease
Randall J Bateman, Jeffrey Cummings, Scott Schobel, et al.
Biorxiv : the Preprint Server for Biology
|
February 9, 2026
Dynamical A <i>β</i> -Tau-Neurodegeneration Model Predicts Alzheimer's Disease Mechanisms and Biomarker Progression
Pavanjit Chaggar, Jacob W Vogel, Travis B Thompson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 14, 2022
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients
Ruben Smith, Nicholas C Cullen, Alexa Pichet Binette, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
January 31, 2025
Biomarker treatment effects in two phase 3 trials of gantenerumab
Tobias Bittner, Matteo Tonietto, Gregory Klein, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 3, 2014
The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data
Mark E Schmidt, Ping Chiao, Gregory Klein, et al.
Page
of 7